↓ Skip to main content

Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor

Overview of attention for article published in Journal for Immunotherapy of Cancer, January 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)

Mentioned by

twitter
15 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
38 Dimensions

Readers on

mendeley
44 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
Published in
Journal for Immunotherapy of Cancer, January 2017
DOI 10.1186/s40425-016-0205-2
Pubmed ID
Authors

Julia Escandon, Stephanie Peacock, Asaad Trabolsi, David B. Thomas, Ayman Layka, Jose Lutzky

Abstract

Immune checkpoint inhibitors have become the first line therapy in melanoma treatment and their use is extending to other malignancies. However, we are still learning about immune side effects produced by these drugs and their severity especially in patients with history of inflammatory diseases. We present two cases of metastatic melanoma treated with nivolumab and pembrolizumab (anti PD-1). Both patients developed acute interstitial nephritis during immune checkpoint therapy. We emphasize the causal association between immune checkpoint inhibitors and the nephritis. The timing of drug administration and appearance of nephritis is suggestive of a causal relation between the checkpoint inhibitor therapy and this adverse event. Although uncommon, some side effects from checkpoint inhibitors can be severe and may need to be addressed with immunosuppression. Given the increasing frequency of immunotherapy use, awareness should be raised in regards to immune side effects and their appropriate management.

Twitter Demographics

The data shown below were collected from the profiles of 15 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 44 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 14%
Student > Master 6 14%
Other 5 11%
Student > Bachelor 5 11%
Student > Ph. D. Student 4 9%
Other 9 20%
Unknown 9 20%
Readers by discipline Count As %
Medicine and Dentistry 22 50%
Biochemistry, Genetics and Molecular Biology 3 7%
Agricultural and Biological Sciences 1 2%
Nursing and Health Professions 1 2%
Immunology and Microbiology 1 2%
Other 2 5%
Unknown 14 32%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 April 2018.
All research outputs
#2,742,325
of 17,875,664 outputs
Outputs from Journal for Immunotherapy of Cancer
#489
of 1,823 outputs
Outputs of similar age
#66,311
of 365,317 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 1 outputs
Altmetric has tracked 17,875,664 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,823 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.7. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 365,317 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them